Back to top

Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints

Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Bayer Aktiengesellschaft (BAYRY)

Exelixis, Inc. (EXEL)

Roche Holding AG (RHHBY)